Interv Akut Kardiol. 2024;23(2-3):136-138 | DOI: 10.36290/kar.2024.015
The CASTLE HTx trial showed a significant reduction in the primary composite endpoint in patients with advanced heart failure with reduced ejection fraction and atrial fibrillation who were treated with catheter ablation in addition to optimal medical treatment of heart failure. Catheter ablation was compared with optimal medical treatment alone. The primary endpoint was a composite of death from any cause, implantation of a left ventricular assist device, and urgent heart transplantation.
Received: July 31, 2024; Revised: July 31, 2024; Accepted: August 19, 2024; Published: December 12, 2024 Show citation
PDF will be unlocked 12.12.2025 |